38 results about "Hcv vaccine" patented technology

The present invention features nucleic acid constructs that can be used as a HCV nucleic acid vaccine, vaccine component, or in the production of a HCV vaccine. Described constructs include those: (1) encoding for a chimeric HCV polypeptide containing a NS3-4A region based on a first HCV strain and an NS3-NS4A-NS4B-NS5A or an NS3-NS4A-NS4B-NS5A-NS5B region based on a second strain; and (2) a chimpanzee based adenovector encoding an HCV polypeptide.

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a / 1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Disclosed are methods and compositions for inducing immune responses against Hepatatis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation.

Disclosed herein are improved anti-HCV immunogens and nucleic acid molecules encoding them. Disclosed immunogens include those having consensus sequences HCV genotype 1a, including, for example, NS4B, NS5A, and NS5B. Disclosed herein are pharmaceutical compositions, recombinant vaccines and live attenuated vaccines containing the same, as well as methods of inducing an immune response against HCV in an individual.

An anti-HCV vaccine, which is prepared through recombination of an NS gene in series, including NS3 / NS4 and NS4 / NS5, with an adenovirus vector. The preparation methods and uses of the anti-HCV vaccine.

The present invention relates to biomedicine technology. HCV envelope protein E2 mediates the combination between HCV and target cell and is key protein relates to HCV infection and one kind of low expression protein hard to obtain in gene recombination process. The present invention aims at provides high efficiency secretion method for mammal to express HCV envelope protein E2. The method constitutes one new type of mammal cell expressing plasmid, which expresses target gene E2 protein in high level while expressing glutamine synthetase as the screening marker in low level. The present invention makes it possible to batch prepare recombinant HCV envelope protein E2 with the natural biological function and antigenicity of HCV envelope protein, lays the foundation for development of serological HCV infection detecting reagent and HCV vaccine, and provides HCV molecular virological research with important material.

The invention discloses an adenovirus vector and its application in preparing HCV (hepatitis C virus) cells and mouse models. The invention provides a recombinant adenovirus vector which is obtained by inserting nucleotides shown by the sequence 1 in the sequence table in the adenovirus vector HDAd (helper-dependent adenovirus). The experiments prove that the invention provides a third generation adenovirus vector of a recombinant HCV 2a type full-length genome, the prepared adenovirus can be used for preparing HCV whole-genome cell models or mouse models, and the obtained models can be used for drug screening of anti-HCV drugs, so as to be used for HCV vaccine evaluation and researches of the pathogenic mechanism.

The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1 / E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1 / E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1 / E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1 / E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

The invention is a hepatitis C virus (HCV) compound multi-epitope transgene edible plant vaccine. The HCV vaccine is obtained by expressing the HCV compound multi-epitope antigen gene in a plant expression host system, and the plant expression host is edible. The invention provides an efficient and cheap HCV vaccine which can provide cross-protection against different types and different HCV isolates.